SCHEMBL17296016

SCHEMBL17296016

CSc1ncc(Br)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844034 0.73
SCHEMBL1535168 0.72
SCHEMBL22923802 0.71
SCHEMBL11326408 0.71
SCHEMBL25432118 0.71
SCHEMBL19347989 0.71 MEN1 (0.33)
SCHEMBL15309667 0.70 PTGES (0.40)
SCHEMBL10808342 0.68 MEN1 (0.34)
SCHEMBL12547392 0.68 MEN1 (0.34)
SCHEMBL31374089 0.67 MEN1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079878-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof 2026-05-26 CN disclosed
CN-122079879-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof 2026-05-26 CN disclosed
CN-122079880-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof 2026-05-26 CN disclosed
EP-4192454-B1 AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES SKYHAWK THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20260085045-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2026-03-26 US disclosed
US-12577226-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
US-12497366-B2 Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-12-16 US disclosed
US-20250333397-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC (US) 2025-10-30 US disclosed
US-20250326722-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2025-10-23 US disclosed
EP-4590397-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2025-07-30 EP disclosed
US-10040788-B2 1,3,4-thiadiazole compounds and their use in treating cancer ASTRAZENECA AB (SE) 2018-08-07 US disclosed
US-10040788-B2 1,3,4-thiadiazole compounds and their use in treating cancer ASTRAZENECA AB (SE) 2018-08-07 US disclosed
EP-3148994-B1 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2018-07-11 EP disclosed
EP-3148994-B1 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2018-07-11 EP disclosed
US-20170197954-A1 1,3,4-Thiadiazole compounds and their use in treating cancer ASTRAZENECA AB (SE) 2017-07-13 US disclosed
US-20170197954-A1 1,3,4-Thiadiazole compounds and their use in treating cancer ASTRAZENECA AB (SE) 2017-07-13 US disclosed
US-20170197954-A1 1,3,4-Thiadiazole compounds and their use in treating cancer ASTRAZENECA AB (SE) 2017-07-13 US disclosed
EP-3148994-A1 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2017-04-05 EP disclosed
WO-2015181539-A1 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2015-12-03 WO disclosed
WO-2015181539-A1 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2015-12-03 WO disclosed